MEGA logo

Mega Lifesciences Public Company Limited Stock Price

SET:MEGA Community·฿30.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author

MEGA Share Price Performance

฿0
-25.00 (-100.00%)
฿41.14
Fair Value
฿0
-25.00 (-100.00%)
Price ฿0

MEGA Community Narratives

·
Fair Value ฿41.14 16.1% undervalued intrinsic discount

Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value ฿45 23.3% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Drive Wellness Demand

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value ฿35 1.4% undervalued intrinsic discount

Myanmar Scrutiny And FX Risks Will Dampen Prospects With Upside

1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
฿35
1.4% undervalued intrinsic discount
Revenue
4.8% p.a.
Profit Margin
15.34%
Future PE
15x
Price in 2029
฿43.13
฿45
23.3% undervalued intrinsic discount
Revenue
7.57% p.a.
Profit Margin
15.7%
Future PE
17.43x
Price in 2029
฿55.46

Trending Discussion

Updated Narratives

MEGA logo

MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside

Fair Value: ฿41.14 16.1% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MEGA logo

MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued

Fair Value: ฿35 1.4% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
1 users have liked this narrative
MEGA logo

MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook

Fair Value: ฿45 23.3% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet, good value and pays a dividend.

1 Risk
3 Rewards

Mega Lifesciences Public Company Limited Key Details

฿14.6b

Revenue

฿6.9b

Cost of Revenue

฿7.7b

Gross Profit

฿5.6b

Other Expenses

฿2.1b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 13, 2026
2.37
52.55%
14.13%
4.6%
View Full Analysis

About MEGA

Founded
1982
Employees
n/a
CEO
Vivek Dhawan
WebsiteView website
www.megawecare.com

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, including medical and sports nutrition, general well-being, vitamins, probiotics, herbal medicines, and cough and cold medicines, as well as hair, kid’s, men’s, and women’s care products; and various health concerns products, such as allergy, bone and joint, gut, liver, diabetic, eye, heart, brain, sleep and anxiety, pain, and skin care, as well as blood circulation and memory. The company also provides prescription medicines for anti-allergic, anti-infective, cardiovascular system, central nervous system, dermatology, diabetes, gastrointestinal, gynecology, nephrology, oncology, ophthalmology, orthopedic, pain, respiratory, rheumatology, and urology areas under the MEGA We care brand name. In addition, it offers logistical and marketing services for trading and sale of goods manufactured by third parties comprising warehouse management, collections, and value-added services; natural and plant-based health foods; digital support solutions; and operation of wellness center. Further, the company is involved in social enterprise; and software design, development, and other services. It sells its products in in Southeast Asia, Sub-Saharan Africa, Australia, Europe, and South America. Mega Lifesciences Public Company Limited was incorporated in 1982 and is headquartered in Bangkok, Thailand.

Recent MEGA News & Updates

Narrative Update Jun 07

MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside

Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.
Narrative Update May 24

MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside

Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).

Recent updates

No updates

Mega Lifesciences Public Company Limited Competitors